News | January 02, 2025
Innovent inks agreement with Roche for Novel DLL3 ADC
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Subscribe To Our Newsletter & Stay Updated
